SRDX
Surmodics, Inc.
Set alert
- YTD
- +8.54%
- 1 year
- +9.50%
- Open
- 42.98
- Prev close
- 42.98
- Mkt cap
- 564.90M
- Vol
- 5.34M
- Avg vol
- 203.31K
- EPS
- -0.82
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 42.98
- High
- 42.98
- Forward P/E
- 141.14
- Beta
- 1.20
- Short ratio
- 1.62
- Inst. own
- 84.22%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 6, 2025
- 50-d avg
- 38.89
- 200-d avg
- 37.09
- 1y target
- 43.00
Key statistics
- Market cap
- 564.90M
- Enterprise value
- 553.45M
- Trailing P/E
- 0.00
- Forward P/E
- 141.14
- PEG ratio
- 0.00
- Price / sales
- 4.48
- Price / book
- 4.72
- EPS (TTM)
- -0.82
- Beta
- 1.20
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -9.16%
- Revenue (TTM)
- 126.08M
- Revenue growth
- 18.80%
- Free cash flow
- 7.61M
- Total cash
- 40.11M
- Total debt
- 29.55M
- Return on equity
- -9.67%
- Shares outstanding
- 14.29M
- Short % of float
- 3.18%
- 50-day average
- 38.89
- 200-day average
- 37.09
Analyst view
Consensus: none
- Strong buy0
- Buy0
- Hold3
- Sell0
- Strong sell0
Next earnings
Feb 6, 2025
Expected Feb 6, 2025. Consensus EPS estimate -0.11667.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 6, 2025 | Dec 1, 2024 | -0.08 | — | — | — |
| Nov 6, 2024 | Sep 1, 2024 | -0.27 | -0.13 | +0.14 | +51.85% |
| Jul 31, 2024 | Jun 1, 2024 | -0.31 | -0.27 | +0.04 | +12.90% |
| May 1, 2024 | Mar 1, 2024 | -0.36 | 0.07 | +0.43 | +119.44% |
| Feb 1, 2024 | Dec 1, 2023 | -0.35 | 0.00 | — | — |
| Nov 8, 2023 | Sep 1, 2023 | 0.16 | 0.53 | +0.37 | +231.25% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 7, 2024 | Needham | reit | — | Hold |
| Aug 5, 2024 | Needham | reit | — | Hold |
| May 30, 2024 | Barrington Research | down | Outperform | Market Perform |
| May 29, 2024 | Lake Street | down | Buy | Hold |
| May 29, 2024 | Sidoti & Co. | down | Buy | Neutral |
| May 29, 2024 | Needham | down | Buy | Hold |
About Surmodics, Inc.
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- surmodics.com
News
- Brokerages Set Surmodics, Inc. (NASDAQ:SRDX) Target Price at $43.00
- Medtech Integer Could Be More Valuable As A Private Company - Activist Investor Urges Strategic Review
- Groupe la Francaise Sells 33,700 Shares of Surmodics, Inc. $SRDX
- Surmodics Announces FTC Does Not Intend to Appeal Denial of Injunction, Order Preventing Closing Set to Expire Today
- Dow Gains More Than 300 Points; Energy Vault Holdings Shares Jump
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- Federal Judge Clears Path For GTCR's Takeover Of Surmodics After FTC Challenge
- PubMatic Posts Upbeat Q3 Results, Joins Energy Vault, RealReal And Other Big Stocks Moving Higher On Tuesday
- US Stocks Mixed; Sea Shares Gain After Q3 Results
- Surmodics Announces U.S. District Court Denies Request for Preliminary Injunction to Block Proposed Acquisition by GTCR
Your note
Sign in to keep a note on SRDX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARENS TIMOTHY J. | Chief Financial Officer | Sale | Nov 25, 2024 | 70,350 |
| BEDOYA JOSE H | Director | Stock Award(Grant) | Feb 7, 2024 | 28,957 |
| DANTZKER DAVID R | Director | Stock Award(Grant) | Feb 7, 2024 | 39,124 |
| HEINE LISA WIPPERMAN | Director | Stock Award(Grant) | Feb 7, 2024 | 13,453 |
| KALICH RONALD B SR | Director | Stock Award(Grant) | Feb 7, 2024 | 38,278 |
| KNIGHT SUSAN E | Director | Stock Award(Grant) | Feb 7, 2024 | 35,148 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.18% | 1,169,670 | 46.23M | Sep 29, 2024 |
| Alliancebernstein L.P. | 7.28% | 1,040,430 | 41.12M | Sep 29, 2024 |
| Beryl Capital Management LLC | 6.92% | 988,904 | 39.08M | Sep 29, 2024 |
| Vanguard Group Inc | 5.62% | 803,508 | 31.75M | Sep 29, 2024 |
| Morgan Stanley | 5.27% | 752,706 | 29.75M | Sep 29, 2024 |
| Soleus Capital Management, L.P. | 4.46% | 637,698 | 25.20M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.95% | 422,044 | 16.68M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.45% | 350,868 | 13.87M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.54% | 220,432 | 8.71M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.98% | 140,668 | 5.56M | Aug 30, 2024 |
| DFA U.S. Small Cap Series | 0.83% | 118,517 | 4.68M | Jul 30, 2024 |
| Gabelli ABC Fund | 0.69% | 99,000 | 3.91M | Sep 29, 2024 |